| Patent Number |
Title Of Patent |
Date Issued |
| 7393541 |
Mycobacterial vaccine |
July 1, 2008 |
| Compositions and methods for enhancing the immunity of a subject or vaccinating a subject against mycobacterial infections are disclosed. The invention provides compositions comprising formalin inactivated cultures of a mycobacterium, such as M. bovis, and a Novasome.RTM. adjuvant, as |
| 7041500 |
Insect cell line |
May 9, 2006 |
| An insect cell line capable of growth in serum-free media and secretion of high levels of recombinant proteins, including virus-like particles, upon infection with recombinant baculoviruses, is provided. Methods involving clonal selection processes, serum-weaning and recombinant protein |
| 6458562 |
Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods an |
October 1, 2002 |
| The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to p |
| 6387373 |
Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
May 14, 2002 |
| The present invention features an adjuvanted vaccine, and methods for preparing an adjuvanted vaccine, preferably for immunizing against influenza, where the adjuvant is a lipid vesicle, and preferably is a nonphospholipid, paucilamellar lipid vesicle. The antigen may be encapsulated |
| 6060066 |
Method for treating tumors with a toxin |
May 9, 2000 |
| A method for treating a tumor is provided, which comprises the steps of preliminarily immunizing a patient in need of antitumor treatment with a toxin or toxin surrogate vaccine in an amount which is effective to generate an immune response to the toxin in the patient, thereby providing |
| 6054567 |
Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods an |
April 25, 2000 |
| The invention relates to the expression of open reading frame 2 (ORF-2) proteins of a strain of hepatitis E virus from Pakistan (SAR-55) in a eukaryotic expression system. The expressed proteins can serve as an antigen in diagnostic immunoassays and/or as an immunogen or vaccine to p |
| 6034073 |
Solvent detergent emulsions having antiviral activity |
March 7, 2000 |
| Methods and pharmaceutical compositions for inactivating an envelope virus using an oil-in-water emulsion including an oil, a surfactant, and an organic phosphate-based solvent are disclosed. These methods can be used to inactivate a wide variety of envelope viruses, such as HIV. |
| 5795582 |
Adjuvant properties of poly (amidoamine) dendrimers |
August 18, 1998 |
| A new method of adjuvanting a variety of materials has been developed. Starburst dendrimers, primarily poly(amidoamine) starburst dendrimers, can be used as an adjuvant for Influenza antigen and similar materials. Mid-Generation dendrimers are preferred and yield high antibody titer |
| 5730989 |
Oral vaccine against gram negative bacterial infection |
March 24, 1998 |
| The present invention concerns an oral preparation useful as an immunizing agent or vaccine against gram negative bacterial infection. This oral preparation can also be used as a treatment for those infected with gam negative bacteria. The preparations can be used against any gram negati |
| 5700679 |
Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity |
December 23, 1997 |
| A novel formulation having anti-viral and spermicidal properties has been developed. The formulation contains lipid vesicles having an outer bilayer formed of a non-ionic amphiphile, a surfactant such as having spermicidal and/or anti-viral activity, an oil and a sterol. The selection of |
| 5667786 |
Method for treating tumors with a toxin |
September 16, 1997 |
| A method for treating a tumor is provided, which comprises the steps of preliminarily immunizing a patient in need of antitumor treatment with a toxin or toxin surrogate vaccine in an amount which is effective to generate an immune response to the toxin in the patient, thereby providing |
| 5662957 |
Oil containing lipid vesicles with marine applications |
September 2, 1997 |
| Disclosed is a new class of lipid vesicles, liposoils, which have high oil content, low water content, and protein. The liposoils are made using a combination of a surfactant and either dried egg yolk or dried whole egg as the wall material, oil, and an aqueous diluent. Unlike most lipid |
| 5629021 |
Micellar nanoparticles |
May 13, 1997 |
| The present invention relates to micellar nanoparticles and methods of their production. Micellar nanoparticles are made by hydrating a mixture of an oil, a stabilizer/surfactant, and an alcoholic initiator with an aqueous solution. These micellar nanoparticles are normally less than 100 |
| 5618840 |
Antibacterial oil-in-water emulsions |
April 8, 1997 |
| An antibacterial oil-in-water emulsion for inhibiting the growth of Helicobacter pylori is disclosed. The oil-in-water emulsion of the invention comprises droplets of an oily discontinuous phase dispersed in a continuous phase. The oily discontinuous phase contains an oil carrier and |
| 5549901 |
Antimicrobial oil-in-water emulsions |
August 27, 1996 |
| An antimicrobial lipid-containing oil-in-water emulsion comprising an agent selected from the group consisting of glycerol monooleate, glycerol trioleate, glycerol monolaurate, and glycerol dilaurate as the primary lipid and a cationic halogen-containing compound having a C.sub.12 -C |
| 5547677 |
Antimicrobial oil-in-water emulsions |
August 20, 1996 |
| An antimicrobial lipid-containing oil-in-water emulsion comprising an agent selected from the group consisting of glycerol monooleate, glycerol trioleate, glycerol monolaurate, and glycerol dilaurate as the primary lipid and a cationic halogen-containing compound having a C.sub.12 -C |
